Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 282,390
  • Shares Outstanding, K 23,396
  • Annual Sales, $ 30,930 K
  • Annual Income, $ -38,920 K
  • 60-Month Beta 1.78
  • Price/Sales 9.13
  • Price/Cash Flow N/A
  • Price/Book 2.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.54
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.59
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.50 +22.60%
on 06/06/19
12.55 -7.17%
on 06/11/19
+0.95 (+8.88%)
since 05/14/19
3-Month
8.88 +31.19%
on 05/07/19
14.36 -18.87%
on 03/25/19
+1.58 (+15.69%)
since 03/14/19
52-Week
5.49 +112.20%
on 11/28/18
14.36 -18.87%
on 03/25/19
+4.59 (+65.01%)
since 06/14/18

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on May 31, 2019, it issued an inducement award to Don Kalkofen, the Company's recently hired Chief Financial Officer, in accordance with...

PTGX : 11.65 (-3.48%)
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced results from the initial single ascending dose (SAD) part of the Phase 1 study of PN-943, an oral, gut-restricted alpha-4-beta-7 integrin specific...

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics: 1Q Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Wednesday reported a loss of $14.1 million in its first quarter.

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics Reports First Quarter 2019 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the first quarter ended March 31, 2019. The Company also announced changes to the executive management team, with the...

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of...

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Larry Mattheakis, Ph.D., SVP Discovery Biology and Translational Research, will present results of preclinical studies of PN-943, an oral,...

PTGX : 11.65 (-3.48%)
Report: Exploring Fundamental Drivers Behind Visteon, Senseonics, Concert Pharmaceuticals, Cincinnati Bell, Protagonist Therapeutics, and THL Credit -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Visteon Corporation (NASDAQ:VC),...

PTGX : 11.65 (-3.48%)
SENS : 2.00 (-6.10%)
CNCE : 10.76 (-2.36%)
CBB : 5.42 (-0.73%)
TCRD : 6.59 (+1.23%)
VC : 52.27 (-0.42%)
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright & Co. Global Life Sciences Conference...

PTGX : 11.65 (-3.48%)
Protagonist Therapeutics: 4Q Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Tuesday reported a loss of $13.9 million in its fourth quarter.

PTGX : 11.65 (-3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PTGX with:

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

2nd Resistance Point 12.25
1st Resistance Point 11.95
Last Price 11.65
1st Support Level 11.47
2nd Support Level 11.29

See More

52-Week High 14.36
Last Price 11.65
Fibonacci 61.8% 10.97
Fibonacci 50% 9.92
Fibonacci 38.2% 8.88
52-Week Low 5.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar